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Abstract 
Purpose of review. To summarize findings, discuss problems and define new 
questions from the past phase III trials in anaplastic gliomas. 
Recent findings. The current standard of care for first-line treatment in anaplastic 
gliomas is radio- or chemotherapy. The next steps are to define the role and optimal 
sequencing of combined modality treatment focusing on radiotherapy and 
temozolomide and to develop trials with novel targeted treatments. The feature of 
necrosis in oligodendroglial tumors needs to be further studied, and molecular 
prognosticators will take more room. These include O6-
methylguanylmethyltransferase promoter methylation, isocitrate dehydrogenase 
mutations and epidermal growth factor receptor amplification. Further, the notion that 
all anaplastic oligodendroglial tumors with or without a relevant astrocytic component 
fall into the same prognostic category and the obvious difficulties to type and to 
grade anaplastic gliomas pose an enormous burden on local diagnosis. The current 
and up-coming trials including the EORTC 26053/22054 trial aim at solving some of 
these issues with an initial central pathology review.  
Summary. Anaplastic gliomas are an important group of brain tumors to develop 
future molecularly targeted therapies and should therefore be in the main focus of 
academic and industrial drug development, which aims at efficacy and avoiding long-
term side-effects.  
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Introduction 
About 6-10% of all newly diagnosed primary brain tumors in adults are considered to 
be WHO grade III tumors or anaplastic gliomas: anaplastic astrocytoma (AA), 
anaplastic oligoastrocytoma (AOA) or anaplastic oligodendroglioma (AO). After three 
randomized phase III trials (1-3), the standard of care for all anaplastic gliomas is to 
use postoperative radio- or chemotherapy alone despite the frequent common 
practice to embark on regimens developed for the treatment glioblastoma (4-6). A 
part of this discrepancy between science and daily practice is explained by the 
diagnostic uncertainties that is associated both with typing and grading of gliomas as 
well as the obvious room for improvement in glioma therapy. Enriching patient 
populations with comparable prognosis via easier and more objectively defined or at 
least complementary molecular parameters such as deletions of 1p/19q, 
hypermethylation of CpG residues in the promotor of the O6-methyl-guanyl-methyl-
transferase (MGMT) gene or mutations in codon 132 of the isocitrate dehydrogenase 
(IDH)1 gene might help to differentiate between those who need maximal primary 
treatments and those who do better regardless of treatments with (late) side effects 
as one major concern. 
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Review 
This review focuses on the current clinical standard after four randomized trials in the 
past years, the important molecular translational data and the critical questions for 
further diagnostic, clinical and translational development. 
 
Clinical situation 
The common practice of care for AA is to use postoperative radiotherapy alone or to 
embark on regimens developed for the treatment of malignant gliomas in general, 
i.e., AA plus glioblastoma or glioblastoma (4-6). The prognostic impact of the surgical 
resection remains a field of controversy because of the scarcity of prospective clinical 
data. Although not uniformely assessed by early postoperative imaging as in the 5-
aminolevulinic acid (ALA) trial (7), but judged by the neurosurgeon, analysis of 
surgical data from the NOA-04 trial makes a strong point for the prognostic value of a 
gross total resection (3).  
The standard of care in oligodendroglial tumors is biased by the conclusions that 
have been drawn from the landmark work of Gregory Cairncross and David Louis 
introducing procarbazine, lomustine and vincristine (PCV) chemotherapy as well as 
1p/19q deletions as a molecular marker into the treatment of these tumors with the 
notion that chemo- and not as discovered later - therapy sensitivity is the reason for 
relative success of treating these tumors (8). Consequently, all large trials in the past 
years have also focused on PCV. In contrast to glioblastoma (9) and a German trial 
(5), it was felt that sequencial radio- and chemotherapy, but not the immediate 
combination of both could improve outcome. 
 
EORTC 26951/RTOG 94-02/NOA-04: What are the questions and key answers? 
In the United States the phase III Radiation Therapy Oncology Group (RTOG) study 
(R9402) aimed at improving progression-free survival (PFS) with radiotherapy and 
preceding PCV in patients with anaplastic oligodendroglial tumors. In Europe the 
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contemporaneous study of the European Organization for Research and Treatment 
of Cancer (EORTC) (26951) used the same comparators but completed radiotherapy 
before commencing PCV and used overall survival (OS) as primary endpoint. Both 
trials showed increased PFS but not OS in patients receiving radiochemotherapy, 
gained at the cost of significant toxicity with the PCV regimen (1,2).  
The phase-III trial on all anaplastic gliomas conducted by the Neurooncology 
Working Group (NOA) of the German Cancer Society (NOA-04 trial) was designed to 
study sequencing of therapies by comparing efficacy and safety of radiotherapy 
versus chemotherapy (temozolomide or PCV) and using an adapted cross-over at 
progression. Radiotherapy and chemotherapy elicited comparable therapeutic results 
and the outcome of AO and AOA was identical and more favorable as compared to 
AA (3). The median OS data of this trial are in the range of 80 months, stressing the 
relevance to be care for long-term (neuro)toxicity similar to prior low-grade glioma 
trials (10).  
 
Dilemma in diagnostic neuropathology 
Areas of major subjectivity in diagnostic neuropathology that are not clearly regulated 
in the current WHO classification are the differentiation between grade II and III 
astrocytoma, the classification of oligodendroglial tumors with necrosis and the 
diagnosis of a mixed glioma, i.e. an oligoastrocytoma. 
 
Difficulties in typing and grading 
The revised 2007 World Health Organization classification of brain tumors no longer 
accepts the diagnosis “mixed AOA” if necrosis is present; these tumors should be 
considered glioblastomas (perhaps with oligodendroglial features). In the EORTC 
26951 trial this notion is supported; in addition the feature of necrosis is prognostic in 
the pure oligodendroglial tumors allowing four groups (AO +/- necrosis and AOA +/- 
necrosis) (11); given that NOA-04 did not find a prognsotic difference between AO 
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and AOA and that the EORTC 26951 most likely contained up to a third 
glioblastoma, the relevance of necrosis in pure OA needs to be readdressed in the 
NOA-04 trial. Upgrade from II to III is mainly reached by comparably higher 
cellularity, nuclear atypia and mitotic activity and more marked pleomorphism. A 
threshold for the diagnosis of a mixed anaplastic glioma is missing. These data are 
leading to the following scenario. 
 
Interobserver variability 
A set of 114 tumors from EORTC 26951 was reviewed independently by nine 
internationally reknowned pathologists, Collins, Figarella, Giannini, Giangasparo, 
Kros, Mokhtari, Mork, Paetau, and Reifenberger. In this set of anaplastic 
oligodendroglial tumors according to study entry criteria, the panel diagnosed a low-
grade glioma in 1-16%, an anaplastic astroycytoma in up to 11% and a glioblastoma 
in 1-27% (12). A similar exercise was done on the material from the RTOG 94-02 trial 
that had a central review to begin with to differentiate classical from non-classical 
oligodendroglial histologies. Because of soft criteria, interobserver variability was 
again higher than wished with a Cohen’s kappa of 0.55 (95% CI 0.44-0.65) (13). In 
addtion to other confounding factors at study entry and the eminent problem to 
compare trials, this intrinsic typing and grading variability leads to major differences 
in outcome parameters when EORTC 26951, RTOG 94-02 and NOA-04 are 
compared (Table).    
 
Guidance when to use local and central pathology review 
In NOA-04, AO and AOA patients showed virtually identical outcomes, although 
previous data indicated a less favourable prognosis for AOA patients (14). A rather 
restrictive central histological AOA classification classified astrocytic tumours with 
just minute or ambiguous oligodendroglial differentiation features not into the AOA 
group, but into the AA group. This approach separated two prognostically distinct 
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anaplastic glioma groups; AA vs. AO and AOA. The findings argue that tumors with 
an unequivocal and quantitatively significant oligodendroglial component, in addition 
to astrocytic tumour parts, should qualify for a mixed oligoastrocytic glioma 
diagnosis. This approach may help to constrain the increase in oligodendroglial 
tumour diagnoses in recent years (15). The considerable discordance even between 
experienced neuropathologists concerning the histopathological diagnosis in EORTC 
26951 (12) and the differences in absolute numbers between the trials with closer 
results between the North American and the German trial, both relying on central 
review prior to study start (Table) argues for central pathology review prior to study 
entrance. Further, consideration has to be given how results of trials with central 
histopatholgy are transferred to the daily clinical routine outside clinical trials. There, 
treatment decisions will be based on local histopathology. Emphasize should be put 
on introducing molecular markers to the WHO classification to reduce the subjective 
elements of diagnosis. 
 
What is the role of imaging? 
Before the pathological entry criteria are unified tackling imaging questions may 
seem premature. However, closer correlations between histology and magnetic 
resonance imaging (MRI) parameters, such as perfusion-weighted imaging or MR 
spectroscopy (16) or positron-emmission tomography (PET) (17) might add to the 
decision of typing and grading in anaplastic tumors. Further, pooling of imaging data 
to work on growth and recurrence patterns (18) is warranted.  Larger, collaborative 
approaches with standardized imaging protocols like the German Glioma Network 
(www.gliomnetzwerk.de) will be necessary to substantiate the initial findings. 
 
Molecular markers  
Attempts have been made to correlate clinical outcome with specific predictive 
markers in the tumor tissue, including genetic deletions, particularly combined 
Wick & Weller 
 8
deletion of chromosomal arms 1p and 19q (8), hypermethylation / gene silencing of 
specific promoters, notably the MGMT gene promoter in glioblastomas (19), or gene 
amplification particularly in growth factor receptors and cell cycle regulatory events 
(20). 
 
Classical 1p/19q 
Deletion of 1p and 19q predicts a superior outcome in anaplastic glioma patients 
treated with radiotherapy or chemotherapy (3,8) but not in patients with low-grade 
oligodendroglial tumors treated with surgery alone (21). In a reanalysis of EORTC 
26951, the 1p/19q codeletion was mainly diagnosed in AO, associated with growth in 
the frontal lobe and was the strongest positive prognostic marker retaining relevance 
also in the multivariate analysis (11) which, however, did not include MGMT and 
IDH1. Today, 1p/19q deletions are understood to occur by an unbalanced 
translocation of 19p to 1q t(1;19)(q10;p10) (22,23), prognostic in both AA and 
AO/AOA for either radio- or chemotherapy and not predictive for a therapy modality 
and useful for entry into a clinical trial (EORTC 26053/22054 at www.eortc.be).  
 
The two-headed MGMT: outlook to solve the problem 
MGMT is a ubiquitous DNA repair enzyme, which is associated with resistance to 
alkylating agent cancer therapy (24). The MGMT promoter methylation status 
determined by MSP is the strongest prognostic factor for outcome of newly 
diagnosed glioblastoma patients and a powerful predictor of response to alkylating 
chemotherapy (19,25-28). The strong correlation between response to temozolomide 
and the MGMT promoter methylation status with patients with a methylated MGMT 
promoter gaining benefit from the addition of temozolomide whereas those who did 
not have a methylated MGMT promoter did have a significantly worse survival and 
less benefit from the addition of temozolomide to radiotherapy (OS rate at 24 
months: 14% vs. <2 %) (19). This raises the question if the small benefit from 
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chemoirradiation observed in this group outweighs the toxicity and costs of the 
temozolomide treatment, and calls for the development of more effective drug 
regimens for this specific group of patients. Although there may be small numbers of 
patients with an unmethylated MGMT promoter that do benefit from combined 
chemo-irradiation and relevant issues remain for the best modus of determination of 
MGMT status, for the entire subgroup of these molecularly defined patients the 
overall benefit is questionable. One attempt to answer this question has led to the 
development of trials according to MGMT status with intensification of temozolomide-
containing radiochemotherapy for patients with methylated MGMT promoter and 
replacement of the alkylating agent (temozolomide) by non-MGMT substrates that 
may synergistically act with radiotherapy like enzastaurin (29,30) or temsirolimus 
(www.eortc.be). 
The NOA-04 trial showed no difference in PFS or overall survival in patients started 
on radiotherapy alone versus those started on temozolomide or PCV alone and 
MGMT promoter methylation predicted prolonged PFS irrespective of the initial 
treatment (3). Similar results as in the NOA-04 were obtained in an analysis of tumor 
samples from the EORTC trial 26951 in that MGMT promoter methylation was 
prognostic for PFS in both arms, radiotherapy alone and radiotherapy followed by 
PCV (van den Bent et al. accepted for publication at J Clin Oncol 2009). The high 
correlation of MGMT promoter methylation with the 1p/19q co-deletion (3,31), that is 
a known favorable prognostic factor in anaplastic glioma (1-3), indicates a distinct 
pathogenetic context of the epigenetic deregulation of MGMT in anaplastic gliomas. 
There is emerging evidence, e.g. in anaplastic gliomas that the relevance of MGMT 
promoter methylation may extend beyond the prediction of chemosensitivity, 
signifying a distinct molecular profile. MGMT promoter methylation may be predictive 
for the response to alkylating chemothrapy in glioblastoma, but is mainly prognostic 
or predictive for both radio- and chemotherapy in anaplastic gliomas (3, van den Bent 
et al. accepted for publication at J Clin Oncol 2009). Ongoing research aims at 
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providing the data for a „methylator“ (with methylated MGMT) versus an non-
methylator (with unmethylated) MGMT anaplastic glioma subtype. 
 
IDH1: the new kid on the block. 
IDH1 was very recently identified as mutated in only 8-12% of primary glioblastomas, 
but in 60-70% of low-grade and anaplastic gliomas and associated with clinical 
outcome (32-34). The NOA-04 trial provided the first analysis of the significance of 
IDH1 mutations in codon 132 as a novel important positive prognostic marker in the 
context of a prospective clinical trial (3).  
Emerging molecular parameters call for a ranking amongst these prognosticators. In 
NOA-04 IDH-1 was more important than MGMT and histology, allowing a pure AA 
with IDH1 mutation the same prognosis as an AO/OA with the alteration. Similarly, 
an AA with IDH1 mutation had a much better prognosis than AO/AOA without this 
mutation (3 and unpublished data). In a nutshell and somewhat oversimplifying a 
wish to a good fairy in Neuropathology could be either IDH1 mutation or MGMT 
promoter methylation or with somewhat lesser impact the presence or absence of an 
unequivocal oligodendroglial component.  
 
Developing new standards for newly diagnosed and recurrent disease 
Neurooncologists have to face the fact that two large randomized trials failed to 
improve OS with therapy intensification even in oligodendroglial tumors, which had 
previously been regarded specifically therapy-sensitive, but may in fact be 
insensitive, albeight prognostically better.  
 
Improving radio- or chemotherapy 
The notion of relative chemosensitivity comes from the fact that 1p/19q-deleted 
tumors showed a trend towards better PFS when treated with PCV in addition to 
radiotherapy in the EORTC 26951 and RTOG 94-02 trials (1,2,35). Further, the 
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analysis of an old trial, EORTC 26882, on the addition of dibromodulcitol and 
bichloroethylnitrosourea to radiotherapy in anaplastic astrocytoma also suggested a 
trend for improved PFS and OS in the chemotherapy arm (36). In contrast, 
glioblastoma patients obviously benefit from therapy intensification both 
postsurgically at diagnosis (6,27,37) and at recurrence (38,39). Looking at objective 
response rates (40), even complicates the picture since glioblastoma rarely respond 
and neither in glioblastoma nor in anaplastic glioma response seems to predict 
survival (41). 
The precise determinators of sensitivity to genotoxic therapy remain obscure. The 
molecular explanation for the greater sensitivity of 1p/19q-codeleted tumors could, in 
part, be explained by more frequent MGMT promoter gene methylation. Other hints 
may be found in data from glioma-initiating cells that display a differential therapeutic 
sensitivity compared to the tumor bulk and potentially are located in a protected 
niche. Therefore, treatment intensification per se might be of limited value for 
anaplastic gliomas with a good prognosis, which is conferred by a mutated IDH1 
gene, a methylated MGMT promoter or a diagnosis of an oligodendroglial tumor, 
whereas the other cohort might benefit from a treatment approach similar to 
glioblastoma with the emphasis on the concomitant chemo-radiotherapy.  However, 
there are concerns regarding late neurotoxicity related to the administration of 
concurrent chemoradiotherapy, manifesting itself particularly as cognitive decline as 
seen in patients with primary CNS lymphoma (42). For glioblastoma patients, this is 
probably not a major concern, as few patients will live long enough to experience late 
toxicity. However, this could be a real concern for AA patients who may potentially 
live for several years with adverse effects of treatment that would substantially 
impact on the quality of the additional time they may gain from combined modality 
treatment. This concern is another argument for opting in worse prognosis patients 
and an argument for using temozolomide which maybe safely applied over several 
years (43).  
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What is the role of molecularly-defined therapies? 
Molecularly targeted therapies may theoretically be more effective and less toxic than 
traditional cytotoxic chemotherapy. Results of the first targeted therapy trials for 
malignant gliomas have been disappointing. While inhibiting vascular endothelial 
growth factor (VEGF) in recurrent glioblastoma with a humanized antibody, 
bevacizumab, has been promising and later approved in the US (44,45), other single-
agent drugs have been largely unsuccessful when tested in recurrent disease clinical 
trials. These single agents included EGFR inhibitors (gefitinib and erlotinib), the 
platelet-derived growth factor receptor inhibitor imatinib, inhibitors of mammalian 
target of rapamycin, temsirolimus and everolimus, as well as protein kinase C-beta 
and other angiogenesis pathway inhibitors like vatalanib and enzastaurin (reviewed 
in 46,47) or most recently the immune modulator, polyinosinic-polycytidylic acid 
stabilized with polylysine and carboxymethylcellulose (poly-ICLC) in a mono-
compound recurrence trial in AA (48).  
Similar to recurrent glioblastoma, a phase II trial in recurrent anaplastic gliomas 
demonstrated interesting activity of two bevacizumab (10 mg/kg every 14 days or 15 
mg/kg every 3 weeks) / irinotecan (every 14 days or on days 1, 8, 22 and 29 every 6 
weeks) regimens. The response rate was remarkable (61% partial responses 
according to 40) and the PFS at 6 months high with 55% (49). Given that it is difficult 
to find more impressive data in the literature it is hard to understand that a 
randomized trial – per se minimizing selection biases - is missing and that the role of 
irinotecan obviously needs to be redefined in anaplastic glioma after limited activity 
was demonstrated in glioblastoma (45).   
Nonetheless, since most of these trials have been done in glioblastoma and with 
single compounds, the role of these treatments in the different subgroups of 
anaplastic gliomas needs to be analyzed. These tumors may serve as excellent 
paradigms to test the activity of new compounds and combinations due to a slower 
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course of disease and possibly a different biology, at least in the AO/AOA subgroup. 
More specifically, immune-modulatory approaches involving anti-transforming growth 
factor beta strategies and vaccination that rely on minimal residual tumor burden as 
well as on the interval necessary to generate an immune response and therapies that 
aim at interfering with the dedifferentiation that occurs with the malignant 
transformation in most grade III tumors are prime candidates for being tested in 
anaplastic gliomas.   
 
Conclusions 
IDH1-mutated (50) or MGMT-methylated or oligodendroglial or 1p/19q-codeleted 
(better-prognosis) anaplastic tumors are rare, diffusely infiltrating neoplasias, arising 
in the white matter of the cerebral hemispheres, and displaying a better prognosis 
and possibly sensitivity to treatment than other anaplastic gliomas. There are no 
known predictive factors to stratify for specific treatments, and even the MGMT 
status is purely prognostic and not, as in glioblastoma, predictive for alkylating agent 
chemotherapy. 
Treatment of choice of all anaplastic gliomas consists of resection as extensive and 
as safe possible and is preferentially within trials that aim at defining the role for 
concomitant radiochemotherapy with temozolomide or evaluating novel compounds. 
Outside trials, these tumors can be focally irradiated or treated with standard 
temozolomide or other alkylating agents, especially lomustine and procarbazine. At 
recurrence, the complementary treatment is given or again, trials are to be designed 
with antiangiogenic, antiinvasive, differentiating or immune-modulatory compounds. 
Future research will define the differential biology of the better-prognosis anaplastic 
tumors.  
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RTOG 94-02 RT PCV + RT 
Median PFS, months [95% CI] 20.4 [15.6-28.8] 31.2 [22.8-49.2] 
Median OS, months [95% CI] 56.4 [40.8-68.4] 58.8 [39.6-86.4] 
EORTC 26951 RT RT + PCV 
Median PFS, months [95% CI] 13.0 [9.2-19.4] 23.0 [17.6-43.8] 
Median OS, months 30.6 [21.9-45.3] 40.3 [28.7-68.2] 
NOA-04 RT PCV or TMZ 
Median PFS, months [95% CI] 52.1 [36.4-n.r] 52.7 [33.9-n.r.] 
Median OS 84+ 84+ 
 
